To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

NCT04593758 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma, Clear Cell

Interventions

DRUG: CPI-613 + Hydroxychloroquine

Sponsor

Cornerstone Pharmaceuticals